Showing 5041-5050 of 8550 results for "".
- Shay Mitchell Signs on as Brand Ambassador for Bioré's New Baking Soda Cleansershttps://practicaldermatology.com/news/shay-mitchell-signs-on-as-brand-ambassador-for-biors-new-baking-soda-cleansers/2458619/Actress Shay Mitchell is the face of Bioré® for 2016, and will be featured in upcoming campaigns for the brand’s new Baking Soda cleansers. Mitchell will help launch The Bioré® Baking Soda Pore Cleanser an
- Melanoma Cells Grow More Aggressive with Agehttps://practicaldermatology.com/news/melanoma-cells-grow-more-aggressive-with-age/2458622/Aged tumor cells in melanoma tend to be metastatic and more resistant to treatment compared with younger tumor cells, according to an international team led by researchers out of The Wistar Institute in Philadelphia. The findings, which appear in
- Galderma, Mentor Worldwide, LLC Set to Collaboratehttps://practicaldermatology.com/news/galderma-mentor-worldwide-llc-set-to-collaborate/2458623/Galderma and Mentor Worldwide LLC, are joining forces to increase awareness and provide a broader range of offerings to healthcare providers and patients seeking aesthetic injectable treatments and breast enhancement. Data shows up to 33% of women
- Rosacea Awareness Month Highlights Potential Increased Health Riskshttps://practicaldermatology.com/news/rosacea-awareness-month-highlights-potential-increased-health-risks/2458624/New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the
- Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe ADhttps://practicaldermatology.com/news/next-stop-fda-approval-dupilumab-improves-symptoms-in-moderate-to-severe-ad/2458625/Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) granted dupilumab Breakthrough Therapy designation in AD in November 2014. U.S. regulatory
- Victoria Kennedy receives ASLMS' First Leadership, Mentorship & Public Advocacy for Women in Medical Science Awardhttps://practicaldermatology.com/news/victoria-kennedy-receives-aslms-first-leadership-mentorship-public-advocacy-for-women-in-medical-science-award/2458628/Victoria Reggie Kennedy will receive the first Leadership, Mentorship & Public Advocacy for Women in Medical Science Award at the annual meeting of the American Society for Laser Medicine and Surgery (ASLMS). The award will be presented at th
- More Than 1,000 Patients Join Corrona Psoriasis Registryhttps://practicaldermatology.com/news/more-than-1000-patients-join-corrona-psoriasis-registry/2458631/The Corrona Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, now includes more than 1,000 patients from 100 sites. Dermatologists assess registry pa
- Take That, Melanoma! New Patch Delivers Anti-PD-1 Antibodies Directly to Skin Cancerhttps://practicaldermatology.com/news/take-that-melanoma-new-patch-delivers-anti-pd-1-antibodies-directly-to-skin-cancer/2458633/A new patch embedded with microneedles may deliver anti-PD-1 antibodies directly to the site of melanoma, according to a study in Nano Letters. In animal studies, the technique more effectively targeted
- Let the Sun Shine In? Research Reveals Why Sunbathers May Live Longer than Sun Avoidershttps://practicaldermatology.com/news/let-the-sun-shine-in-research-reveals-why-sunbathers-may-live-longer-than-sun-avoiders/2458634/Sunbathers tend to live longer than their shade-seeking counterparts despite their increased risk for skin cancer, but why? New research suggests that a decrease in heart disease and noncancer/non-heart disease deaths may explain the paradox.
- Profounda Launches Impavido for Visceral, Mucosal and Cutaneous Leishmaniasishttps://practicaldermatology.com/news/profounda-launches-impavido-for-visceral-mucosal-and-cutaneous-leishmaniasis/2458636/Profounda, Inc. launched Impavido (miltefosine) in the United States. Impavido is the first oral treatment for visceral, mucosal and cutaneous leishmaniasis approved by the FDA and the first Rx product launched in the US by Profounda. Although skin sores of cutaneous leishmaniasis (CL) us